Drugs /

zalifrelimab

Back to Drugs List

Overview

NCI Definition [1]:
A recombinant human monoclonal antibody directed against the human T-cell receptor cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, anti-CTLA-4 monoclonal antibody AGEN1884 binds to CTLA-4 expressed on T-cells and inhibits the CTLA-4-mediated downregulation of T-cell activation. This leads to a cytotoxic T-lymphocyte (CTL)-mediated immune response against cancer cells. CTLA-4, an inhibitory receptor and member of the immunoglobulin superfamily, plays a key role in the downregulation of the immune system.

Clinical Trials

View Clinical Trials for zalifrelimab

Zalifrelimab has been investigated in 6 clinical trials, of which 5 are open and 1 is closed. Of the trials investigating zalifrelimab, 2 are phase 1/phase 2 (2 open) and 4 are phase 2 (3 open).

Cervical adenocarcinoma, cervical adenosquamous carcinoma, and cervical squamous cell carcinoma are the most common diseases being investigated in zalifrelimab clinical trials [2].

Drug Details

Synonyms [2]:
agen1884, agen-1884, anti-ctla-4 monoclonal antibody agen1884
Drug Target(s) [2]:
CTLA4
NCIT ID [1]:
C126113

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.